Intrexon acquires operations from Codexis and expands presence to Europe

US synthetic biology firm Intrexon (NYSE: XON) has acquired state-of-the-art laboratory operations in Budapest, Hungary, from Codexis, a developer of biocatalysts for the pharmaceutical and complex chemistry industries.

The acquisition, financial terms of which were not disclosed, will expand Intrexon's strain and protein development capabilities, as well as strengthen fermentation process optimization and scale-up. Through the agreement, Intrexon's Industrial Products Division (IPD) will absorb the Budapest laboratory staff of experienced scientific professionals. Integration of the Budapest team and their expertise with Intrexon's suite of synthetic biology technologies and capabilities will allow Intrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients (API) and industrial and consumer product collaborations.

Includes bioproduction of APIs